Recognizing Euglycemic Diabetic Ketoacidosis in the Era of SGLT2 Inhibitors: A Case Report
Jose C Serrano Reyes, Maria F Carrillo, Rolando L Jaen, Astrid J Batista · 2026
Read Recognizing Euglycemic Diabetic Ketoacidosis in the Era of SGLT2 Inhibitors: A Case Report by Jose C Serrano Reyes, Maria F Carrillo, Rolando L Jaen, Astrid J Batista (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13570715.txt.
Description
Jose Serrano Reyes and three colleagues present a 2026 case report on a dangerous diabetes complication that hides behind normal blood sugar. The condition, euglycemic ketoacidosis, is increasingly tied to SGLT2 inhibitor drugs. Because glucose stays near normal, doctors can miss it while acid builds in the blood.
Their patient was a fifty-one-year-old man with long-standing, poorly controlled type 2 diabetes who fell ill soon after starting a drug pairing empagliflozin with metformin. He arrived weak, with gut symptoms, little appetite, and heavy urination. Labs showed acid blood and ketones despite a glucose of only 160. Intensive care with fluids, insulin, and close monitoring cleared the problem fully. The authors urge suspicion whenever such patients eat poorly.
Catalog record
| CREATOR | Jose C Serrano Reyes, Maria F Carrillo, Rolando L Jaen, Astrid J Batista |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 14 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |